NO20091691L - Pegylert PTH som PTH-reseptormodulatorer og anvendelse derav - Google Patents
Pegylert PTH som PTH-reseptormodulatorer og anvendelse deravInfo
- Publication number
- NO20091691L NO20091691L NO20091691A NO20091691A NO20091691L NO 20091691 L NO20091691 L NO 20091691L NO 20091691 A NO20091691 A NO 20091691A NO 20091691 A NO20091691 A NO 20091691A NO 20091691 L NO20091691 L NO 20091691L
- Authority
- NO
- Norway
- Prior art keywords
- pth
- pegylated
- receptor modulators
- pth receptor
- mammal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Abstract
Farmasøytiske sammensetninger og fremgangsmåter er tilveiebrakt for behandling og hindring av bentapsykdommer som inkluderer osteoporose hos pattedyr.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82938306P | 2006-10-13 | 2006-10-13 | |
PCT/US2007/080367 WO2008048784A1 (en) | 2006-10-13 | 2007-10-04 | Pegylated pth as pth receptor modulators and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20091691L true NO20091691L (no) | 2009-05-11 |
NO341986B1 NO341986B1 (no) | 2018-03-12 |
Family
ID=42828673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20091691A NO341986B1 (no) | 2006-10-13 | 2009-04-28 | Pegylert PTH som PTH reseptor modulatorer, sammensetninger inneholdende slike og anvendelser derav |
Country Status (16)
Country | Link |
---|---|
US (1) | US7820179B2 (no) |
EP (1) | EP2084183B1 (no) |
JP (1) | JP5200027B2 (no) |
KR (1) | KR101108354B1 (no) |
CN (1) | CN101522709B (no) |
AT (1) | ATE469173T1 (no) |
AU (1) | AU2007313001B2 (no) |
BR (1) | BRPI0719885B8 (no) |
CA (1) | CA2672907C (no) |
DK (1) | DK2084183T3 (no) |
EA (1) | EA014696B1 (no) |
MX (1) | MX2009003740A (no) |
NO (1) | NO341986B1 (no) |
PL (1) | PL2084183T3 (no) |
SI (1) | SI2084183T1 (no) |
WO (1) | WO2008048784A1 (no) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201806092TA (en) * | 2016-03-01 | 2018-08-30 | Ascendis Pharma Bone Diseases As | Pth prodrugs |
US11590207B2 (en) * | 2016-09-29 | 2023-02-28 | Ascendis Pharma Bone Diseases A/S | Dosage regimen for a controlled-release PTH compound |
KR102611820B1 (ko) * | 2016-09-29 | 2023-12-07 | 아센디스 파마 본 디지즈 에이/에스 | 낮은 피크 대 트로프 비를 가진 pth 화합물 |
WO2019232280A1 (en) * | 2018-05-30 | 2019-12-05 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
FR2550204B1 (fr) | 1983-08-05 | 1987-11-13 | Toyo Jozo Kk | Derives peptidiques de (nle8,nle1b, tyr34)-h-pth |
JPS6360940A (ja) | 1986-09-01 | 1988-03-17 | Toyo Jozo Co Ltd | 白内障の予防または治療剤 |
US4771124A (en) | 1987-05-26 | 1988-09-13 | Merck & Co., Inc. | Parathyroid hormone antagonists with simplified synthetic methodology |
EP0293158A3 (en) | 1987-05-26 | 1990-05-09 | Merck & Co. Inc. | Parathyroid hormone antagonists |
JPH0532696A (ja) | 1990-09-28 | 1993-02-09 | Takeda Chem Ind Ltd | 副甲状腺ホルモン誘導体 |
JPH05271279A (ja) | 1991-08-07 | 1993-10-19 | Takeda Chem Ind Ltd | ヒト副甲状腺ホルモンムテインおよびその製造法 |
US5814603A (en) | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
US5589452A (en) | 1992-07-14 | 1996-12-31 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
AU672790B2 (en) | 1992-07-15 | 1996-10-17 | Novartis Ag | Variants of parathyroid hormone and its fragments |
CA2126299C (en) | 1994-06-20 | 2000-12-12 | Gordon E. Willick | Parathyroid hormone analogues for the treatment of osteoporosis |
US6110892A (en) | 1994-06-20 | 2000-08-29 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
US5747456A (en) | 1994-12-19 | 1998-05-05 | Beth Israel Deaconess Medical Center | Continuous low-dose administration of parathyroid hormone or its agonist |
US5717062A (en) | 1995-06-07 | 1998-02-10 | Beth Israel Hospital Association | Cyclic analogs of PTH and PTHrP |
CA2178894A1 (en) | 1995-06-15 | 1996-12-16 | Tsunehiko Fukuda | Parathyroid hormone derivatives and their use |
US5723577A (en) | 1995-07-13 | 1998-03-03 | Biomeasure Inc. | Analogs of parathyroid hormone |
US5955574A (en) | 1995-07-13 | 1999-09-21 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. | Analogs of parathyroid hormone |
US6544949B1 (en) | 1995-07-13 | 2003-04-08 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Analogs of parathyroid hormone |
NZ333809A (en) | 1996-08-02 | 2000-07-28 | Ca Nat Research Council | Parathyroid hormone analogues for use as medicaments in treating osteoporosis |
KR100351213B1 (ko) * | 1997-05-14 | 2002-09-05 | 아벤티스 파마슈티칼스 인크. | 펩타이드 부갑상선 호르몬 유사체 및 이를 포함하는 약제학적 조성물 |
JP2001519384A (ja) * | 1997-10-14 | 2001-10-23 | イーライ・リリー・アンド・カンパニー | 骨の構築と維持のための方法 |
IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
CN1163504C (zh) | 1998-04-15 | 2004-08-25 | 阿温蒂斯药物公司 | 制备与树脂结合的环状肽的方法 |
WO1999057139A2 (en) | 1998-05-05 | 1999-11-11 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Pth2 receptor selective compounds |
US6316410B1 (en) | 1999-09-22 | 2001-11-13 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
US7022815B1 (en) | 1999-09-29 | 2006-04-04 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (PTH) |
WO2001023521A2 (en) | 1999-09-29 | 2001-04-05 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (pth) |
US20050124537A1 (en) | 2000-04-27 | 2005-06-09 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
WO2003009804A2 (en) | 2001-07-23 | 2003-02-06 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (pth) analogs |
WO2003064462A1 (fr) | 2002-02-01 | 2003-08-07 | Chugai Seiyaku Kabushiki Kaisha | Pth a liaison peg ou derive de pth a liaison peg |
US7799757B2 (en) | 2002-06-13 | 2010-09-21 | Michael Chorev | Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents |
TW533925U (en) | 2002-09-26 | 2003-05-21 | Lee Yeong Ind Co Ltd | Improvement of speed-changing transmission mechanism for cutting tools of drill sharpening machine |
AU2002359391A1 (en) | 2002-11-01 | 2004-07-29 | Amgen, Inc. | Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein |
US7432330B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
EP1607095A1 (en) * | 2003-03-25 | 2005-12-21 | Sekisui Chemical Co., Ltd. | Antipruritic composition for external use on skin |
US20040220094A1 (en) | 2003-05-01 | 2004-11-04 | Skinner Keith K. | Inverse agonist and agonist peptides that stimulate/inhibit hair growth |
US20050215476A1 (en) | 2004-01-21 | 2005-09-29 | Unigene Laboratories Inc. | Amidated parathyroid hormone fragments and uses thereof |
-
2007
- 2007-10-04 PL PL07843791T patent/PL2084183T3/pl unknown
- 2007-10-04 SI SI200730296T patent/SI2084183T1/sl unknown
- 2007-10-04 CN CN2007800382095A patent/CN101522709B/zh not_active Expired - Fee Related
- 2007-10-04 EA EA200970376A patent/EA014696B1/ru not_active IP Right Cessation
- 2007-10-04 MX MX2009003740A patent/MX2009003740A/es active IP Right Grant
- 2007-10-04 US US12/440,619 patent/US7820179B2/en not_active Expired - Fee Related
- 2007-10-04 KR KR1020097007424A patent/KR101108354B1/ko active IP Right Grant
- 2007-10-04 EP EP07843791A patent/EP2084183B1/en active Active
- 2007-10-04 BR BRPI0719885A patent/BRPI0719885B8/pt not_active IP Right Cessation
- 2007-10-04 WO PCT/US2007/080367 patent/WO2008048784A1/en active Application Filing
- 2007-10-04 AU AU2007313001A patent/AU2007313001B2/en not_active Ceased
- 2007-10-04 DK DK07843791.0T patent/DK2084183T3/da active
- 2007-10-04 CA CA2672907A patent/CA2672907C/en not_active Expired - Fee Related
- 2007-10-04 JP JP2009532504A patent/JP5200027B2/ja not_active Expired - Fee Related
- 2007-10-04 AT AT07843791T patent/ATE469173T1/de active
-
2009
- 2009-04-28 NO NO20091691A patent/NO341986B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BRPI0719885B1 (pt) | 2018-12-11 |
DK2084183T3 (da) | 2010-08-16 |
NO341986B1 (no) | 2018-03-12 |
BRPI0719885A2 (pt) | 2014-04-29 |
JP2010506844A (ja) | 2010-03-04 |
PL2084183T3 (pl) | 2010-10-29 |
CA2672907C (en) | 2013-08-06 |
CN101522709A (zh) | 2009-09-02 |
ATE469173T1 (de) | 2010-06-15 |
MX2009003740A (es) | 2009-04-22 |
KR101108354B1 (ko) | 2012-01-25 |
CN101522709B (zh) | 2013-03-20 |
EA200970376A1 (ru) | 2009-10-30 |
WO2008048784A1 (en) | 2008-04-24 |
BRPI0719885B8 (pt) | 2021-05-25 |
AU2007313001B2 (en) | 2012-03-22 |
US20090253630A1 (en) | 2009-10-08 |
JP5200027B2 (ja) | 2013-05-15 |
EP2084183B1 (en) | 2010-05-26 |
KR20090067168A (ko) | 2009-06-24 |
EA014696B1 (ru) | 2010-12-30 |
AU2007313001A1 (en) | 2008-04-24 |
EP2084183A1 (en) | 2009-08-05 |
CA2672907A1 (en) | 2008-04-24 |
US7820179B2 (en) | 2010-10-26 |
SI2084183T1 (sl) | 2010-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2443287B (en) | Methods, compositions and formulations for the treatment of thyroid eye disease | |
UY30304A1 (es) | Moduladores de mglur5 i | |
NO20083011L (no) | Modulatorer av muskarine receptorer | |
DK3072507T3 (da) | Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi | |
WO2007077561A3 (en) | Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents | |
UY30308A1 (es) | Moduladores de mglur5 v | |
WO2008115469A3 (en) | Role of hedgehog signaling in atherosclerosis and cardiovascular disease | |
UA95975C2 (ru) | N-метиламинометилизоиндольные соединения, композиции, содержащие их, и способы их применения | |
DK2059243T3 (da) | Buprenorphin-vaffel til lægemiddelsubstitutionsterapi | |
UY30573A1 (es) | N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2 | |
EP1981970A4 (en) | TISSUE CONSTRUCTION TISSUE TREATMENT DERIVED FROM A HUMAN EMBRYONIC STEM CELL | |
MX2012001974A (es) | Compuestos de biarilo y metodos de uso de los mismos. | |
HUE041764T2 (hu) | Kollagén-mediálta betegségek kezelésére alkalmas kompozíciók | |
UY30307A1 (es) | Moduladores de mglur5 vi | |
MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
DK2205558T3 (da) | Substituterede n-phenylpyrrolidinylmethylpyrrolidinamider og terapeutisk anvendelse deraf som histamin-h3- receptormodulatorer | |
UY30306A1 (es) | Moduladores de mglur5 iii | |
NO341679B1 (no) | Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren | |
UY30305A1 (es) | Moduladores de mglur5 iv | |
EP2068865A4 (en) | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | |
UY30309A1 (es) | Moduladores de mglur5 ii | |
NO20084006L (no) | Modulatorer av muskarinreseptorer | |
NO20091691L (no) | Pegylert PTH som PTH-reseptormodulatorer og anvendelse derav | |
EP2102231A4 (en) | IMPROVED EXPRESSION SYSTEM FOR RECOMBINANT HUMAN ARGINASE I | |
HK1131339A1 (en) | Prophylactic or therapeutic agent for viral disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |